从2010年开始，越来越多的优秀中概股企业选择从海外资本市场私有化，并谋求回到估值水平更高的国内资本市场重新上市。中概股私有化的浪潮中需要大量的投资机构参与其中，这股浪潮中也蕴含了巨大的投资机会。随着国内资本市场估值的持续提升，资本市场制度建设的完善，国内资本市场对海外中概股公司的吸引力也会越来越大。本文介绍了中概股私有化的趋势，并从理论和实际两方面剖析了中概股私有化潮流背后的动机。此外，本文还深入分析了中概股私有化的交易方式、交易流程、监管机构的审查重点等实际操作层面的问题。最后，本文挑选了绿叶制药的私有化再上市案例，阐述了私有化再上市的投资方式和逻辑，并试图筛选出符合私有化要求的中概股企业，为中概股私有化的投资作出初步的判断。

From 2010, an increasing number of Chinese concept stock companies opted for privatization, seeking to be listed in the domestic capital market with a higher valuation of assets. The privatization trend of Chinese concept stocks requires extensive participation of investment institutions with a variety of investment opportunities involved. With the valuation of domestic capital market on the rise and regulations being completed, Chinese concept stock companies overseas tend to be more attracted to Chinese domestic market. The article first introduces the privatization trend of Chinese concept stocks and then analyzes the motivation behind the trend both theoretically and practically. This paper introduces the privatization trend of the Chinese concept stocks, and from two aspects of theory and practice to analyzes the motivation behind the waves of privatization delisting. In addition, this paper also analyzes the ownership structure of the Chinese concept stocks and figures out the practical operation issues of the privatization methods, the process, and the focus of the review by the regulators. Lastly, the article elaborates the investing methods and logic based on Luye Pharmaceutical Public-Private-Public case in an attempt to select the companies which meet the requirements of privatization, and provide the preliminary judgement for the privatization of the Chinese concept stocks.